其他最新文献

{"title":"Understanding East-West differences in subsolid nodules: prevalence and overdiagnosis implications in lung cancer screening.","authors":"Yeun-Chung Chang, Yi-Chi Hung, Yun-Ju Wu, En-Kuei Tang, Fu-Zong Wu","doi":"10.1080/07853890.2025.2478321","DOIUrl":"10.1080/07853890.2025.2478321","url":null,"abstract":"<p><strong>Background: </strong>Owing to the widespread opportunistic LDCT screening leading to increased overdiagnosis in Asian countries, such as South Korea, mainland China, and Taiwan, this study seeks to analyze the divergence in SSN prevalence between Eastern and Western nations, focusing on the influence of SSN on the growing overdiagnosis trend, notably among females.</p><p><strong>Methods: </strong>This retrospective study collected data from 4166 participants who underwent baseline LDCT in a hospital-based cohort between January 2014 and August 2021. Clinical parameters, including age, sex, lung imaging reporting and data system (Lung-RADS) categories, smoking history, pack-year dose, and SSN characteristics, were extracted from electronic medical records. Additionally, a narrative review and pooled analysis integrated relevant published studies on the prevalence of subsolid nodules and sex disparities.</p><p><strong>Results: </strong>The study encompassed 4166 participants, with females accounting for 49.3% and males for 50.7%, with a mean age of 53.38 ± 10.89. The prevalence of SSNs was significantly higher in females (20.1%) than in males (12.6%). Pooled analysis across seven studies revealed a significantly higher prevalence of SSN in Eastern countries (12.6%) compared to the prevalence in Western countries (3.6%) (test for subgroup differences: <i>p</i> < 0.01; I² = 100%). Additionally, a notable sex difference was observed in the prevalence of SSNs (risk ratio = 0.489, 95% CI: 0.301-0.796, <i>p</i> < 0.01; reference group: male group).</p><p><strong>Conclusions: </strong>Apart from differences in clinical management and health literacy regarding SSNs between Eastern and Western countries, the high prevalence of SSNs in Asian nations, particularly among females, significantly contributes to the issue of overdiagnosis in opportunistic lung cancer screening in Asian countries. Tailored sex-specific strategies and risk prediction models are essential for effective screening optimization.</p>","PeriodicalId":93874,"journal":{"name":"Annals of medicine","volume":"57 1","pages":"2478321"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912254/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ruxolitinib cream monotherapy for facial and/or neck atopic dermatitis: results from a decentralized, randomized phase 2 clinical trial.","authors":"Zelma C Chiesa Fuxench, Zhihong Lai, YuTzu Kuo, Haq Nawaz, Jonathan Cotliar","doi":"10.1080/09546634.2025.2480744","DOIUrl":"https://doi.org/10.1080/09546634.2025.2480744","url":null,"abstract":"<p><strong>Purpose: </strong>Ruxolitinib cream was evaluated in patients with facial/neck atopic dermatitis (AD) in a decentralized, double-blind, randomized clinical trial (NCT05127421).</p><p><strong>Materials and methods: </strong>Patients aged 12-70 years with AD (Investigator's Global Assessment [IGA] score 2/3, ≤20% affected body surface area [face/neck, ≥0.5%]) were randomized 2:1 to twice-daily 1.5% ruxolitinib cream or vehicle for 4 weeks; thereafter, all patients applied as-needed ruxolitinib cream for 4 additional weeks. The primary endpoint was ≥75% improvement in head/neck Eczema Area and Severity Index (EASI-75) at Week 4 assessed by blinded central reader using photographs.</p><p><strong>Results: </strong>Among 77 randomized patients (median [range] age, 38.0 [17-66] y), 44.2% were Black. The mean (SD) baseline head/neck EASI was 1.2 (0.7). More patients who applied ruxolitinib cream vs vehicle achieved head/neck EASI-75 at Week 4 (37.0% vs 17.4%; <i>p</i> = 0.091). Improvements with ruxolitinib cream vs vehicle were observed for facial/neck IGA treatment success (IGA 0/1 with ≥2-point improvement from baseline) and Patient-Oriented Eczema Measure (overall and itch). Ruxolitinib cream was well tolerated, including on the face and neck. Application site reactions were infrequent (ruxolitinib cream, 1.9% [<i>n</i> = 1]; vehicle, 8.7% [<i>n</i> = 2]).</p><p><strong>Conclusions: </strong>Ruxolitinib cream improved signs and symptoms of facial/neck AD vs vehicle and was well tolerated.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2480744"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143712640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term prognostic value of thyroid hormone levels in chronic critical illness patients.","authors":"Zhaoxiang Li, Liang Wang, Jianling Shi, Weiying Han, Chengrui Zhu, Tingrui Zhang, Xiaochun Ma, Yingjian Liang","doi":"10.1080/07853890.2025.2479583","DOIUrl":"10.1080/07853890.2025.2479583","url":null,"abstract":"<p><strong>Background: </strong>Chronic critical illness (CCI) can manifest as dysfunction of thyroid hormones. This study aimed to investigate the predictive value of the nonthyroidal illness syndrome (NTIS) for the prognosis of CCI patients, establish a predictive model for the prognosis of CCI patients, and evaluate the efficacy of the model to provide a theoretical basis for clinical intervention.</p><p><strong>Methods: </strong>This was a prospective observational study in which patients ≥18 years old who met the CCI criteria were enrolled. The primary outcome of the study was 90-day mortality after intensive care unit (ICU) admission. A nomogram was constructed to predict the prognosis of CCI patients, and the model was evaluated via the concordance index, calibration curve and decision curve analysis.</p><p><strong>Results: </strong>A total of 545 patients were included, and NTIS patients accounted for 65.3% of the patients. CCI patients with NTIS had more ventilator days and higher 90-day mortality. Lower free triiodothyronine (FT3) levels (<1.19 pmol/L) or reduced free thyroxine (FT₄) levels (<9.655 pmol/L) were significantly associated with reduced survival in CCI patients with NTIS. Older age, a higher Sequential Organ Failure Assessment (SOFA) score, an emergency other than a traumatic operation, and a lower FT4 and thyroid-stimulating hormone level were found to be independent prognostic factors for a fatal outcome in CCI patients. The <i>C</i>-index for the prediction nomogram was 0.734, and the bias-corrected <i>C</i>-index was 0.727. The area under the receiver operating characteristic curve of our prediction model was superior to that of the SOFA and Acute Physiology and Chronic Health Evaluation II scores.</p><p><strong>Conclusions: </strong>Decreased serum FT3 and FT4 concentrations in patients with CCI at admission to the ICU on day 10 are associated with 90-day mortality. Early detection of serum FT3 and FT4 levels could help clinicians target CCI patients at high risk of clinical deterioration.</p>","PeriodicalId":93874,"journal":{"name":"Annals of medicine","volume":"57 1","pages":"2479583"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11934158/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143672068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to letter regarding 'demographic and clinical Features of rosacea in North Jordan: a 10-year University Hospital Retrospective study'.","authors":"Diala Alshiyab, Saleh A Ba-Shammakh","doi":"10.1080/07853890.2025.2482861","DOIUrl":"10.1080/07853890.2025.2482861","url":null,"abstract":"","PeriodicalId":93874,"journal":{"name":"Annals of medicine","volume":"57 1","pages":"2482861"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated expression of ANAPC1 in lung squamous cell carcinoma: clinical implications and mechanisms.","authors":"Xiao-Song Chen, Feng Chen, Shu-Jia He, Yi-Yang Chen, Bang-Teng Chi, Wan-Ying Huang, Yue Wei, Chun-Yan Zhao, Chang Song, Rong-Quan He, Gang Chen, Jin-Liang Kong, Hui-Ping Lu","doi":"10.1080/20565623.2025.2482487","DOIUrl":"10.1080/20565623.2025.2482487","url":null,"abstract":"<p><strong>Aim: </strong>To investigate the comprehensive expression levels and possible molecular mechanisms of Anaphase Promoting Complex Subunit 1 (ANAPC1) in lung squamous cell carcinoma (LUSC).</p><p><strong>Methods: </strong>Data from 2,031 samples were combined to evaluate ANAPC1 mRNA levels, and 118 samples were collected for immunohistochemical (IHC) analysis. High-expression co-expressed genes (HECEGs) associated with ANAPC1 were analyzed for signaling pathways. Clinical significance, immune computations, and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) validation of ANAPC1's role in LUSC were assessed. Molecular docking evaluated binding affinity with potential therapeutics.</p><p><strong>Results: </strong>ANAPC1 mRNA was significantly upregulated in LUSC (SMD = 1.97, 95% CI [1.26-2.67]). Protein-level analysis confirmed this upregulation (<i>p</i> < 0.001). Most HECEGs associated with ANAPC1 were enriched in cell cycle pathways. Higher ANAPC1 expression correlated with poorer survival in LUSC patients (HR = 1.11, 95% CI: 1-1.49). ANAPC1 expression was higher in males and N1-stage vs. females and N0-stage; lower in grade I vs. II/III. Overexpression reduces immune cell infiltration and immunotherapy effectiveness, while knockdown inhibits cell proliferation. Drug sensitivity and docking analyses identified tenovin-1, carboxyatractyloside, and phycocyanobilin as potential antitumor agents targeting ANAPC1.</p><p><strong>Conclusion: </strong>The elevated expression of ANAPC1 might play a role in LUSC advancement and progression through its participation in cell growth-related pathways.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2482487"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abrocitinib alleviates the symptoms of Netherton syndrome and is well tolerated.","authors":"Jun-Ting Tang, Yu-Liang Qin, Wei-Jia Zhao, Ying Tu, Dong-Jie Sun","doi":"10.1080/09546634.2024.2447883","DOIUrl":"https://doi.org/10.1080/09546634.2024.2447883","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the potential genetic basis of Netherton syndrome (NS) through first- and second-generation DNA sequencing techniques. Additionally, we evaluated the therapeutic efficacy of Abrocitinib in NS patients.</p><p><strong>Materials and methods: </strong>We conducted whole-exome sequencing analysis on a pedigree comprising one affected individual with NS. Subsequently, the identified patient was treated with Abrocitinib, and clinical improvements in cutaneous manifestations were systematically assessed.</p><p><strong>Results: </strong>Genetic analysis revealed that the patient harbored compound heterozygous mutations in the SPINK5 gene, including a missense mutation in exon 26 (c.2475G > T, p.Trp825Cys). Following six months of Abrocitinib therapy, the patient exhibited marked improvement in skin rash and overall disease severity.</p><p><strong>Conclusions: </strong>Our findings suggest that SPINK5 missense mutations may contribute to the pathogenesis of NS. Furthermore, Abrocitinib demonstrates promising therapeutic potential in the management of NS, warranting further investigation in larger clinical cohorts.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2447883"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Construction of a novel prognostic model based on lncRNAs-related to DNA damage repair for predicting the prognosis of clear cell renal cell carcinoma.","authors":"Peng Chen, Jian Li, Renli Tian","doi":"10.1080/07853890.2025.2480755","DOIUrl":"https://doi.org/10.1080/07853890.2025.2480755","url":null,"abstract":"<p><strong>Background: </strong>CcRCC has the characteristics of high aggression, high metastasis, high mortality, wide tumour heterogeneity and variable clinical course. The purpose of this study was to explore the potential value of lncRNAs-related to DNA damage repair (DDR) in predicting the prognosis of ccRCC by construction and verification a novel prognostic model.</p><p><strong>Methods: </strong>RNA-seq data and clinical data of ccRCC were downloaded from public databases. Subsequently, Pearson correlation analysis and differential expression analysis were performed to identify DElncRNAs-related to DDR. Then, through univariate Cox analysis and LASSO analysis, the DElncRNAs-related to DDR associated with prognosis were screened for the construction of novel risk score prognostic model. In addition, functional annotation, tumour mutation burden, immune correlation and drug sensitivity analyses were performed based on risk score to assess the characteristics of patients in different risk score groups.</p><p><strong>Results: </strong>Based on univariate Cox analysis and LASSO analysis, four best DElncRNAs-related to DDR were selected. Subsequently, a novel risk score prognostic model based on these four DElncRNAs was constructed through LASSO. Multivariate Cox analysis showed that risk score and age were independent prognostic factors for ccRCC (<i>p</i> < 0.05). Functional enrichment analysis showed that DDR-related biological processes were mainly enriched in the high risk group. The highly mutated genes in the high and low risk groups were the same (VHL, PBRM1 and TTN), but they also had their own unique mutated genes. Pearson correlation analysis showed that the risk score was significantly (<i>p</i> < 0.05) positively correlated with the infiltration degree of CD8 T cells evaluated by six algorithms. In addition, it was found that the high and low risk groups had different sensitivities to the drugs Etoposide, Imatinib, Sorafenib, Bosutinib and Sunitinib.</p><p><strong>Conclusion: </strong>A novel prognostic model was constructed based on four DElncRNAs-related to DDR. The model has satisfactory accuracy in predicting survival of ccRCC patients.</p>","PeriodicalId":93874,"journal":{"name":"Annals of medicine","volume":"57 1","pages":"2480755"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143766036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of risk-stratified biopsy decision pathways incorporating MRI and PSA-derived indicators.","authors":"Pengfei Jin, Ximing Wang, Zhenwei Ding, Liqin Yang, Chenyang Xu, Xu Wang, Fawei Huang","doi":"10.1080/07853890.2024.2446695","DOIUrl":"https://doi.org/10.1080/07853890.2024.2446695","url":null,"abstract":"<p><strong>Objectives: </strong>Develop risk-adapted conditional biopsy pathways utilizing MRI in combination with prostate-specific antigen (PSA) density (PSAD) and the ratio of free to total PSA (f/tPSA), respectively, to enhance the detection of clinically significant prostate cancer (csPCa) while minimizing 'negative' biopsies in low-risk patients.</p><p><strong>Methods: </strong>The Prostate Imaging Reporting and Data System (PI-RADS) category, PSAD, f/tPSA and biopsy-pathology of 1018 patients were collected retrospectively. Subsequently, PSAD and f/tPSA were divided into four intervals, which were then combined with the MRI findings to construct two risk stratification matrix tables. Six biopsy decision pathways were established: three clinical pathways based solely on PSAD and f/tPSA, and three MRI-combined pathways incorporating both PI-RADS and PSA-derived indicators. The biopsy and clinically insignificant PCa (ciPCa) avoidance, csPCa detection rate, and 'negative' biopsies proportion were assessed. Decision curve analysis (DCA) was employed to evaluate the net benefit associated with each pathway.</p><p><strong>Results: </strong>When reporting PI-RADS 1 - 2, PSAD ≥ 0.20 ng/ml/cm³ or f/tPSA ≤ 0.10 were found to be useful for patient stratification. When reporting PI-RADS 3, PSAD ≥ 0.10 - 0.15 ng/ml/cm³ and f/tPSA ≤ 0.16 - 0.25 were helpful in distinguishing the risk of csPCa. The three MRI-combined pathways showed higher csPCa detection rates (94% to 96%) than the three clinical pathways (85% to 91%); 'MRI + PSAD + f/tPSA' demonstrated a high csPCa detection rate of 94% while maintaining the maximum biopsy avoidance and lowest 'negative' biopsy proportion of 40% and 25%, respectively. The DCA showed significantly higher net benefits for three MRI-combined pathways compared to all clinical pathways.</p><p><strong>Conclusions: </strong>The integration of MRI and PSA-derived indicators enables effective patient risk stratification, thereby providing valuable decision-making pathways to enhance the management of csPCa while minimizing 'negative' biopsies.</p>","PeriodicalId":93874,"journal":{"name":"Annals of medicine","volume":"57 1","pages":"2446695"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful treatment of Kimura's disease with dupilumab and review of dupilumab in treating eosinophilic dermatoses.","authors":"Yunhong Zheng, Suju Luo","doi":"10.1080/09546634.2024.2449153","DOIUrl":"https://doi.org/10.1080/09546634.2024.2449153","url":null,"abstract":"","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2449153"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Digital Revolution in Medicine: Applications in Cardio-Oncology.","authors":"Gift Echefu, Ladislav Batalik, Abdulkareem Lukan, Rushabh Shah, Priyanshu Nain, Avirup Guha, Sherry-Ann Brown","doi":"10.1007/s11936-024-01059-x","DOIUrl":"10.1007/s11936-024-01059-x","url":null,"abstract":"<p><strong>Purpose of review: </strong>A critical evaluation of contemporary literature regarding the role of big data, artificial intelligence, and digital technologies in precision cardio-oncology care and survivorship, emphasizing innovative and groundbreaking endeavors.</p><p><strong>Recent findings: </strong>Artificial intelligence (AI) algorithm models can automate the risk assessment process and augment current subjective clinical decision tools. AI, particularly machine learning (ML), can identify medically significant patterns in large data sets. Machine learning in cardio-oncology care has great potential in screening, diagnosis, monitoring, and managing cancer therapy-related cardiovascular complications. To this end, large-scale imaging data and clinical information are being leveraged in training efficient AI algorithms that may lead to effective clinical tools for caring for this vulnerable population. Telemedicine may benefit cardio-oncology patients by enhancing healthcare delivery through lowering costs, improving quality, and personalizing care. Similarly, the utilization of wearable biosensors and mobile health technology for remote monitoring holds the potential to improve cardio-oncology outcomes through early intervention and deeper clinical insight. Investigations are ongoing regarding the application of digital health tools such as telemedicine and remote monitoring devices in enhancing the functional status and recovery of cancer patients, particularly those with limited access to centralized services, by increasing physical activity levels and providing access to rehabilitation services.</p><p><strong>Summary: </strong>In recent years, advances in cancer survival have increased the prevalence of patients experiencing cancer therapy-related cardiovascular complications. Traditional cardio-oncology risk categorization largely relies on basic clinical features and physician assessment, necessitating advancements in machine learning to create objective prediction models using diverse data sources. Healthcare disparities may be perpetuated through AI algorithms in digital health technologies. In turn, this may have a detrimental effect on minority populations by limiting resource allocation. Several AI-powered innovative health tools could be leveraged to bridge the digital divide and improve access to equitable care.</p>","PeriodicalId":35912,"journal":{"name":"Current Treatment Options in Cardiovascular Medicine","volume":"27 1","pages":""},"PeriodicalIF":0.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11600984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142751885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}